[{"id":"e43e3d0d-a928-4113-b0cb-1cb1cbe5fa52","acronym":"","url":"https://clinicaltrials.gov/study/NCT07044908","created_at":"2025-07-05T14:01:51.038Z","updated_at":"2025-07-05T14:01:51.038Z","phase":"Phase 1/2","brief_title":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","source_id_and_acronym":"NCT07044908","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-07-01"},{"id":"08660c39-94ce-46e6-891f-cb32c681d233","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012954","created_at":"2025-06-14T13:57:24.505Z","updated_at":"2025-06-14T13:57:24.505Z","phase":"Phase 1/2","brief_title":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","source_id_and_acronym":"NCT07012954","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-06-10"},{"id":"ddb28914-edb2-4733-8bbd-06431d3d7e9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06856837","created_at":"2025-09-07T01:48:45.276Z","updated_at":"2025-09-07T01:48:45.276Z","phase":"Phase 2","brief_title":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases","source_id_and_acronym":"NCT06856837","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-03-04"},{"id":"f49513f4-2324-4f1a-bfa6-fcc569055fc2","acronym":"STAR-T","url":"https://clinicaltrials.gov/study/NCT05839951","created_at":"2023-05-03T15:04:35.012Z","updated_at":"2025-02-25T12:29:31.860Z","phase":"","brief_title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","source_id_and_acronym":"NCT05839951 - STAR-T","lead_sponsor":"Bayer","biomarkers":" KRAS • MSI","pipe":"","alterations":" ","tags":["KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 04/24/2023","start_date":" 04/24/2023","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-24"},{"id":"cb7ed592-cf61-416e-86bf-22b417e0e5af","acronym":"M21-404","url":"https://clinicaltrials.gov/study/NCT05029882","created_at":"2021-09-01T14:52:59.151Z","updated_at":"2025-02-25T13:53:58.746Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","source_id_and_acronym":"NCT05029882 - M21-404","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • EGFR wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 520","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-20"},{"id":"2c844ff3-38e3-4e1a-ab45-51650b975490","acronym":"ST316-101","url":"https://clinicaltrials.gov/study/NCT05848739","created_at":"2023-05-08T15:04:02.971Z","updated_at":"2025-02-25T14:17:54.068Z","phase":"Phase 1","brief_title":"A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors","source_id_and_acronym":"NCT05848739 - ST316-101","lead_sponsor":"Sapience Therapeutics","biomarkers":" PD-L1 • MSI • BRCA","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • BRCA mutation","tags":["PD-L1 • MSI • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • ST316"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2025-02-17"},{"id":"393ae514-083b-4a6f-a6c0-c472fe56deef","acronym":"KEYNOTE-E59","url":"https://clinicaltrials.gov/study/NCT05083481","created_at":"2021-10-19T15:58:03.788Z","updated_at":"2025-02-25T15:19:18.701Z","phase":"Phase 1/2","brief_title":"A Study of ASP1570 Alone or in Combination With Pembrolizumab or Standard Therapies in Adults With Solid Tumors","source_id_and_acronym":"NCT05083481 - KEYNOTE-E59","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • NTRK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK positive • ALK mutation • NTRK fusion","tags":["EGFR • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK positive • ALK mutation • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • docetaxel • Lonsurf (trifluridine/tipiracil) • ASP1570"],"overall_status":"Recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 10/19/2021","start_date":" 10/19/2021","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-12"},{"id":"411c6656-9452-41f8-a0dc-a43d6083250d","acronym":"KEYNOTE-A91","url":"https://clinicaltrials.gov/study/NCT04701476","created_at":"2021-01-19T20:50:41.794Z","updated_at":"2025-02-25T16:11:01.325Z","phase":"Phase 2","brief_title":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","source_id_and_acronym":"NCT04701476 - KEYNOTE-A91","lead_sponsor":"Teclison Ltd.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • Tirazone (tirapazamine)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-11-22"},{"id":"76a5691d-3c36-403e-ae0a-2107bdb5f547","acronym":"LEAP-017","url":"https://clinicaltrials.gov/study/NCT04776148","created_at":"2021-03-01T13:52:36.340Z","updated_at":"2025-02-25T13:35:46.773Z","phase":"Phase 3","brief_title":"Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)","source_id_and_acronym":"NCT04776148 - LEAP-017","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • KRAS • BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["EGFR • KRAS • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 480","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 02/20/2023","primary_completion_date":" 02/20/2023","study_txt":" Completion: 09/27/2024","study_completion_date":" 09/27/2024","last_update_posted":"2024-10-29"},{"id":"ae39f3e1-b6c3-41e3-9be2-0e22cc46ebd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04808791","created_at":"2021-03-22T11:52:09.750Z","updated_at":"2024-07-02T16:34:25.963Z","phase":"Phase 2","brief_title":"iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","source_id_and_acronym":"NCT04808791","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 07/07/2023","primary_completion_date":" 07/07/2023","study_txt":" Completion: 07/21/2023","study_completion_date":" 07/21/2023","last_update_posted":"2024-06-14"},{"id":"6a7437dd-1b7b-49b8-8341-ff9ad04a3230","acronym":"C-800-25","url":"https://clinicaltrials.gov/study/NCT05608044","created_at":"2022-11-08T15:56:56.796Z","updated_at":"2024-07-02T16:34:59.296Z","phase":"Phase 2","brief_title":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","source_id_and_acronym":"NCT05608044 - C-800-25","lead_sponsor":"Agenus Inc.","biomarkers":" EGFR • BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["EGFR • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-06-04"},{"id":"f7adec30-958d-4721-9a82-00722f4075ec","acronym":"PULSE","url":"https://clinicaltrials.gov/study/NCT03992456","created_at":"2021-01-18T19:37:42.598Z","updated_at":"2024-07-02T16:35:02.247Z","phase":"Phase 2","brief_title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","source_id_and_acronym":"NCT03992456 - PULSE","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type","tags":["EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 10/07/2024","study_completion_date":" 10/07/2024","last_update_posted":"2024-05-21"},{"id":"d6aaa5d1-601e-464f-bad3-4724818101a8","acronym":"INTEGRATEIIb","url":"https://clinicaltrials.gov/study/NCT04879368","created_at":"2023-07-21T01:09:24.991Z","updated_at":"2025-02-25T14:15:58.655Z","phase":"Phase 3","brief_title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","source_id_and_acronym":"NCT04879368 - INTEGRATEIIb","lead_sponsor":"Australasian Gastro-Intestinal Trials Group","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • docetaxel • albumin-bound paclitaxel • Stivarga (regorafenib) • irinotecan • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-15"},{"id":"80befaa4-53a0-4489-baa2-338cc2dfb32a","acronym":"TIBET","url":"https://clinicaltrials.gov/study/NCT04489173","created_at":"2021-01-18T21:34:16.480Z","updated_at":"2024-07-02T16:35:03.947Z","phase":"Phase 2","brief_title":"TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer","source_id_and_acronym":"NCT04489173 - TIBET","lead_sponsor":"Borstkanker Onderzoek Groep","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/25/2020","start_date":" 09/25/2020","primary_txt":" Primary completion: 01/08/2024","primary_completion_date":" 01/08/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-14"},{"id":"2d427c2c-44b2-4d75-9818-a28e1db0dc01","acronym":"CodeBreak 300","url":"https://clinicaltrials.gov/study/NCT05198934","created_at":"2022-01-20T15:53:54.576Z","updated_at":"2024-07-02T16:35:04.260Z","phase":"Phase 3","brief_title":"Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation","source_id_and_acronym":"NCT05198934 - CodeBreak 300","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Lumakras (sotorasib) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 03/12/2025","primary_completion_date":" 03/12/2025","study_txt":" Completion: 03/12/2025","study_completion_date":" 03/12/2025","last_update_posted":"2024-05-13"},{"id":"00d242f0-fa63-4201-9e35-6a3b26211f88","acronym":"","url":"https://clinicaltrials.gov/study/NCT06379399","created_at":"2024-04-23T18:55:21.127Z","updated_at":"2024-07-02T16:35:08.038Z","phase":"Phase 1/2","brief_title":"Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC","source_id_and_acronym":"NCT06379399","lead_sponsor":"Wangxia LV","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-23"},{"id":"c059badf-8a2b-4247-bace-32ba3408645c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03317119","created_at":"2021-01-18T16:22:52.836Z","updated_at":"2024-07-02T16:35:11.068Z","phase":"Phase 1","brief_title":"Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03317119","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRAF • PIK3CA • PTEN","pipe":" | ","alterations":" BRAF mutation • PIK3CA mutation • BRAF wild-type • RAS mutation • RAS wild-type • RAS wild-type + BRAF wild-type • PIK3CA mutation + PTEN mutation","tags":["BRAF • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • PIK3CA mutation • BRAF wild-type • RAS mutation • RAS wild-type • RAS wild-type + BRAF wild-type • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 04/11/2018","start_date":" 04/11/2018","primary_txt":" Primary completion: 07/14/2023","primary_completion_date":" 07/14/2023","study_txt":" Completion: 07/14/2023","study_completion_date":" 07/14/2023","last_update_posted":"2024-04-08"},{"id":"470b1556-c556-4764-aec0-fd65bb7bee1e","acronym":"NOTABLE-308","url":"https://clinicaltrials.gov/study/NCT06343116","created_at":"2024-04-02T17:41:44.202Z","updated_at":"2024-07-02T16:35:11.906Z","phase":"Phase 3","brief_title":"Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06343116 - NOTABLE-308","lead_sponsor":"Biotech Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil) • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-04-02"},{"id":"99425b86-d7f5-4e13-abcd-98632d9960ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04660760","created_at":"2021-01-19T20:42:30.744Z","updated_at":"2024-07-02T16:35:12.122Z","phase":"Phase 2","brief_title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT04660760","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Cyramza (ramucirumab) • Lonsurf (trifluridine/tipiracil) • lexatumumab (ETR2-ST01)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 06/16/2021","start_date":" 06/16/2021","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-04-01"},{"id":"d01d0098-4a6a-4882-a7cc-d6d702df5d85","acronym":"LONGBOARD","url":"https://clinicaltrials.gov/study/NCT04166604","created_at":"2021-01-18T20:19:53.169Z","updated_at":"2024-07-02T16:35:15.429Z","phase":"Phase 2","brief_title":"LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy","source_id_and_acronym":"NCT04166604 - LONGBOARD","lead_sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF wild-type • RAS wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 05/20/2020","start_date":" 05/20/2020","primary_txt":" Primary completion: 11/10/2023","primary_completion_date":" 11/10/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-03-11"},{"id":"5747d944-7a11-4d7b-99fe-396946a9c047","acronym":"RELATIVITY-123","url":"https://clinicaltrials.gov/study/NCT05328908","created_at":"2022-04-14T11:53:47.596Z","updated_at":"2024-07-02T16:35:16.804Z","phase":"Phase 3","brief_title":"A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05328908 - RELATIVITY-123","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • RAS wild-type","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 01/29/2025","primary_completion_date":" 01/29/2025","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2024-03-01"},{"id":"ad15ac21-12e0-4c36-9b7b-f02aadf94665","acronym":"SOREGATT","url":"https://clinicaltrials.gov/study/NCT04450836","created_at":"2021-01-18T21:24:46.331Z","updated_at":"2024-07-02T16:35:16.877Z","phase":"Phase 2","brief_title":"Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04450836 - SOREGATT","lead_sponsor":"UNICANCER","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 11/23/2024","primary_completion_date":" 11/23/2024","study_txt":" Completion: 05/23/2028","study_completion_date":" 05/23/2028","last_update_posted":"2024-03-01"},{"id":"cee8aba7-65f5-4dfb-8178-d79ff5369a64","acronym":"","url":"https://clinicaltrials.gov/study/NCT04999761","created_at":"2021-08-11T15:53:36.773Z","updated_at":"2024-07-02T16:35:19.007Z","phase":"Phase 1","brief_title":"AB122 Platform Study","source_id_and_acronym":"NCT04999761","lead_sponsor":"Taiho Pharmaceutical Co., Ltd.","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Cyramza (ramucirumab) • Lytgobi (futibatinib) • Yutuo (zimberelimab) • Lonsurf (trifluridine/tipiracil) • Jeselhy (pimitespib) • pamufetinib (TAS-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 715","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-02-16"},{"id":"043223c9-1b07-4370-8cca-13212df5199c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05007132","created_at":"2021-08-16T16:54:41.427Z","updated_at":"2024-07-02T16:35:19.202Z","phase":"Phase 2","brief_title":"Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05007132","lead_sponsor":"Dominik Paul Modest","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" RAS mutation • RAS wild-type • KRAS exon 2 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • RAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Vectibix (panitumumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 12/01/2032","study_completion_date":" 12/01/2032","last_update_posted":"2024-02-15"}]